Compare KB Financial Group, Inc. (KB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? KB Financial Group, Inc. trades at $115.25 (market cap $38.56B), while State Street SPDR S&P Biotech ETF trades at $154.45. The key difference: KB Financial Group, Inc. pays a 2.72% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| KB | XBI | |
|---|---|---|
Market Cap | $38.56B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $123.25 | $164.28 |
52-Week Low | $77.50 | $85.16 |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB trades at $120.09, up 0.6% with a bullish technical trend and strong earnings momentum, beating estimates for three consecutive quarters. Revenue grew to $21.23T in 2025 with net income margin expanding to 27.82%. The stock shows solid valuation metrics with P/E of 11.07 and P/B of 1.05, while analyst sentiment is mixed with 33% buy ratings amid ongoing diversification into non-banking segments.
The outlook remains positive given consistent earnings beats and ROE expansion potential, though risks include heavy investing cash outflows and reliance on non-banking growth. Institutional hold ratings suggest cautious optimism, with the stock positioned for stability if diversification succeeds but vulnerable to sector volatility.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
